These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23909028)

  • 61. Hormone receptor-positive breast cancer: the known and the unknown.
    Dawood S; Gonzalez-Angulo AM
    Oncology (Williston Park); 2012 Aug; 26(8):700-1. PubMed ID: 22957402
    [No Abstract]   [Full Text] [Related]  

  • 62. Are stem-like cells responsible for resistance to therapy in breast cancer?
    O'Brien CS; Farnie G; Howell SJ; Clarke RB
    Breast Dis; 2008; 29():83-9. PubMed ID: 19029627
    [No Abstract]   [Full Text] [Related]  

  • 63. The natural history of hormone receptor-positive breast cancer: attempting to decipher an intriguing concept.
    Nagaraj G; Ellis MJ; Ma CX
    Oncology (Williston Park); 2012 Aug; 26(8):696-7, 700. PubMed ID: 22957401
    [No Abstract]   [Full Text] [Related]  

  • 64. Therapeutic significance of sex-steroid hormone receptors in the treatment of breast cancer.
    Leclercq G; Heuson JC
    Eur J Cancer (1965); 1977 Nov; 13(11):1205-15. PubMed ID: 338304
    [No Abstract]   [Full Text] [Related]  

  • 65. Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer.
    Tang Y; Wang Y; Kiani MF; Wang B
    Clin Breast Cancer; 2016 Oct; 16(5):335-343. PubMed ID: 27268750
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A new hypothesis on the role of c-erbB2 oncogene in the progress of breast cancer.
    Petrov SV; Raskin GA; Khasanov RSh
    Bull Exp Biol Med; 2006 Jul; 142(1):94-7. PubMed ID: 17369913
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Rapid progression of hormone receptor-negative breast cancer concomitant with ovarian stimulation--a paradoxon?
    Pukrop T; Bleckmann A; Einspanier A; Binder C
    Ann Oncol; 2009 Dec; 20(12):2020-2. PubMed ID: 19773248
    [No Abstract]   [Full Text] [Related]  

  • 68. Molecular markers for breast cancer diagnosis, prognosis and targeted therapy.
    Lang JE; Wecsler JS; Press MF; Tripathy D
    J Surg Oncol; 2015 Jan; 111(1):81-90. PubMed ID: 25091830
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Fuel, electricity, ER and HER2--a hybrid-car model of breast cancer.
    Saji S; Sato F; Ueno NT
    Nat Rev Clin Oncol; 2012 Jun; 9(7):. PubMed ID: 22665363
    [No Abstract]   [Full Text] [Related]  

  • 70. Use of Multiparameter Tests for Identifying Women with Early Breast Cancer Who Do Not Need Adjuvant Chemotherapy.
    Duffy MJ; McDermott EW; Crown J
    Clin Chem; 2017 Apr; 63(4):804-806. PubMed ID: 28188230
    [No Abstract]   [Full Text] [Related]  

  • 71. Lessons for tumor biomarker trials: vicious cycles, scientific method & developing guidelines.
    Hayes D; Raison C
    Expert Rev Mol Diagn; 2015 Feb; 15(2):165-9. PubMed ID: 25548983
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Reply to letter by Ieni et al.
    Aurilio G; Nolè F; Viale G; Pruneri G
    Eur J Cancer; 2014 Mar; 50(5):1038-9. PubMed ID: 24508454
    [No Abstract]   [Full Text] [Related]  

  • 73. Molecular Concordance Between Primary Breast Cancer and Matched Metastases.
    Krøigård AB; Larsen MJ; Thomassen M; Kruse TA
    Breast J; 2016 Jul; 22(4):420-30. PubMed ID: 27089067
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Progress in breast cancer: overview.
    Arteaga CL
    Clin Cancer Res; 2013 Dec; 19(23):6353-9. PubMed ID: 24298065
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Population and target considerations for triple-negative breast cancer clinical trials.
    Hyslop T; Michael Y; Avery T; Rui H
    Biomark Med; 2013 Feb; 7(1):11-21. PubMed ID: 23387481
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Going beyond genetics to discover cancer targets.
    Sandoval GJ; Hahn WC
    Genome Biol; 2017 May; 18(1):95. PubMed ID: 28532420
    [TBL] [Abstract][Full Text] [Related]  

  • 77. PET imaging of steroid receptor expression in breast and prostate cancer.
    Hospers GA; Helmond FA; de Vries EG; Dierckx RA; de Vries EF
    Curr Pharm Des; 2008; 14(28):3020-32. PubMed ID: 18991716
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Understanding Oestrogen Receptor Function in Breast Cancer and its Interaction with the Progesterone Receptor. New Preclinical Findings and their Clinical Implications.
    Baird RD; Carroll JS
    Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):1-3. PubMed ID: 26548499
    [No Abstract]   [Full Text] [Related]  

  • 79. Practice-changing data in metastatic breast cancer.
    Perez EA
    Clin Adv Hematol Oncol; 2013; 11(10 Suppl 16):7-12. PubMed ID: 24637555
    [No Abstract]   [Full Text] [Related]  

  • 80. Molecular Imaging of Steroid Receptors in Breast Cancer.
    Keigley QJ; Fowler AM; O'Brien SR; Dehdashti F
    Cancer J; 2024 May-Jun 01; 30(3):142-152. PubMed ID: 38753748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.